Chin-Chu Chen
Grape King Bio Ltd, Taiwan
Title: Neuroprotective effects of erinacine A from Hericium erinaceum submerged culture mycelium
Biography
Biography: Chin-Chu Chen
Abstract
Erinacine A, the main representative of erinacines existed only in the Hericium erinaceum mycelium, was found to induce nerve growth factor (NGF) synthesis in vitro, and was proved could cross the blood–brain barrier in vivo. Other studies showed this compound also increased catecholamine and NGF content in the central nervous system of rats. In this study, we investigated the production of erinacine A in 20T fermenter and its identification by use of LC-MS-MS and NMR. Purified erinacine A and mycelium extracts were used to treat PC12 cell line for evaluating neural differentiation. Our results showed that erinacine A induced neural differentiation of PC12 cells in a dose dependent manner. In an in vitro study, we examined the effects of erinacine A on amyloid β-peptide (25-35) induced neurotoxicity in primary cortical neurons. In our in vivo data demonstrated induced neurogenesis by erinacine A in transgenic (APP/PS1) mice. We then investigated the neuroprotective effects of H. erinaceum in a MCAO and Parkinson’s model in rat. Results showed infarct volumes markedly reduced in rat receiving 300 mg/kg H. erinaceum treatment for 5 days prior to 1.5 hr MCAO. Oral treatment of H. erinaceumdry mycelium powder (300 mg/kg) in Parkinson’s disease rats showed increased brain dopamine and tyrosine hydroxylase content. H. erinaceum safety assessment showed no treatment related toxicity in rat garaged up to 3000 mg/kg for 28 consecutive days.
